NCT04398680 2025-12-04
DREAMM 13
GlaxoSmithKline
Phase 1 Withdrawn
Clinical Trials
27 trialsNCT06232707 2024-05-31
ALUMMINATE
Celgene
Phase 3 Withdrawn
NCT05647512 2023-11-18
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
LaNova Medicines Limited
Phase 1/2 Withdrawn
NCT05918250 2023-08-18
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
ModernaTX, Inc.
Phase 1 Withdrawn
NCT02389543 2023-01-26
SLAM
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT02628704 2023-01-26
SCORE
Karyopharm Therapeutics Inc
Phase 2 Withdrawn
NCT04998747 2022-09-27
ProxiMMity-1
Amgen
Phase 1 Withdrawn
NCT03660072 2022-05-27
Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma
Bristol-Myers Squibb
Withdrawn
NCT03492268 2022-05-17
Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma
Bioray Laboratories
Phase NA Withdrawn
NCT05183139 2022-05-03
US MM-7
Takeda
Phase 4 Withdrawn
NCT04918511 2021-11-26
COAST
Oncopeptides AB
Phase 1 Withdrawn
NCT04464889 2021-10-08
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
Phase 1 Withdrawn
NCT02786485 2020-10-05
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Bellicum Pharmaceuticals
Phase 1 Withdrawn
NCT03608501 2020-01-14
IDEALL
Takeda
Phase 2 Withdrawn
NCT03785184 2019-08-28
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
AbbVie
Phase 2 Withdrawn
NCT03221634 2019-03-25
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT02155634 2018-04-10
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Celgene
Phase 3 Withdrawn
NCT02951117 2017-06-05
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
AbbVie
Phase 1 Withdrawn
NCT01410929 2017-01-20
MM
Merit Medical Systems, Inc.
Phase 4 Withdrawn
NCT02756663 2016-11-08
PANORAMA-5
Novartis
Phase 2 Withdrawn
NCT02605356 2016-10-07
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
Bayer
Phase 1/2 Withdrawn
NCT00242528 2015-04-14
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
Novartis
Phase 4 Withdrawn
NCT00706953 2015-04-06
A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Withdrawn
NCT01266811 2013-01-28
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Centocor, Inc.
Phase 3 Withdrawn
NCT01445587 2012-03-26
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma
GlaxoSmithKline
Phase 2 Withdrawn
NCT01452334 2012-02-23
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT00547404 2009-04-23
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma
Piramal Enterprises Limited
Phase 1 Withdrawn